Journey Medical (DERM)
(Delayed Data from NSDQ)
$5.39 USD
-0.07 (-1.28%)
Updated Jul 22, 2024 11:26 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DERM 5.39 -0.07(-1.28%)
Will DERM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DERM
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
Other News for DERM
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
Buy Rating on Journey Medical Corp: DFD-29 Poised to Capture Rosacea Market with Strong Revenue and Patent Position
Journey Medical resumed with a Buy at Roth MKM
Journey Medical Corp Shareholders Back Key Proposals